Latest On Cumberland Pharmaceuticals Inc (CPIX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-24 01:06 EST | News | Cumberland Pharma pulmonary fibrosis IND cleared by FDA | N/A |  |
| 2023-05-14 03:45 EST | News | Cumberland Pharmaceuticals Inc. (CPIX) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-10 01:27 EST | News | Cumberland Pharmaceuticals Non-GAAP EPS of $0.11, revenue of $9.2M | N/A | |
| 2023-03-08 08:15 EST | News | Cumberland Pharmaceuticals Inc. (CPIX) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-07 17:50 EST | News | Cumberland Pharmaceuticals GAAP EPS of -$0.17, revenue of $9.12M | N/A | |
About Cumberland Pharmaceuticals Inc (CPIX):
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care and gastroenterology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, read more... and severe psoriatic arthritis, as well as severe disabling psoriasis. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc and Nordic Group B.V. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
General
- Name Cumberland Pharmaceuticals Inc
- Symbol CPIX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 90
- Last Split Factor2:1
- Last Split Date2007-07-06
- Fiscal Year EndDecember
- IPO Date2009-08-11
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.cumberlandpharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 1.3
- Price/Book (Most Recent Quarter) 1.02
- Enterprise Value Revenue 1.14
- Enterprise Value EBITDA 16.67
Financials
- Most Recent Quarter 2020-12-31
- Next Quarter EPS Estimate -$0.07
- Profit Margin -9%
- Operating Margin -17%
- Return on Assets -4%
- Return on Equity -14%
- Revenue 37.44 million
- Earnings Per Share -$0.29
- Revenue Per Share $2.47
- Gross Profit 28.79 million
- Quarterly Earnings Growth 10.3%
Highlights
- Market Capitalization 48.19 million
- EBITDA 2.79 million
- PE Ratio -1.83
- Analyst Target Price $8.5
- Book Value Per Share $3.14
Share Statistics
- Shares Outstanding 14.92 million
- Shares Float 8.42 million
- % Held by Insiders 4319%
- % Held by Institutions 27.06%
- Shares Short 103304
- Shares Short Prior Month 100744
- Short Ratio 1
- Short % of Float 1%
- Short % of Shares Outstanding 1%
Technicals
- Beta 0.28
- 52 Week High $4.18
- 52 Week Low $2.77
- 50 Day Moving Average 3.32
- 200 Day Moving Average 3.16
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Cumberland Pharmaceuticals Inc (CPIX) Dividend Calendar:
Cumberland Pharmaceuticals Inc (CPIX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Cumberland Pharmaceuticals Inc (CPIX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Cumberland Pharmaceuticals Inc (CPIX) Chart:
Cumberland Pharmaceuticals Inc (CPIX) News:
Below you will find a list of latest news for Cumberland Pharmaceuticals Inc (CPIX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Cumberland Pharmaceuticals Inc (CPIX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Cumberland Pharmaceuticals Inc (CPIX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-09 | 8-K (Current report) | |
| 2020-08-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-14 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-11 | 8-K (Current report) | |
| 2020-07-24 | 10-Q/A (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-06-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-29 | 8-K (Current report) | |
| 2020-05-22 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-05-20 | 8-K (Current report) | |
| 2020-05-08 | 8-K (Current report) | |
| 2020-05-08 | 8-K (Current report) | |
| 2020-05-01 | 8-K (Current report) | |
| 2020-04-21 | 8-K (Current report) | |
| 2020-04-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-04-17 | 4 (Statement of changes in beneficial ownership of securities) | |
Cumberland Pharmaceuticals Inc (CPIX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cumberland Pharmaceuticals Inc (CPIX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 4319%
Institutional Ownership: 2706%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-26 | Joseph C Galante | Director | Buy | 225.00 | 3.29 | 740.25 | 24,892.00 | |
| 2020-08-21 | Joseph C Galante | Director | Buy | 375.00 | 3.35 | 1,256.25 | 24,667.00 | |
| 2020-08-14 | Joseph C Galante | Director | Buy | 375.00 | 3.44 | 1,290.00 | 24,292.00 | |
| 2020-06-09 | Joseph C Galante | Director | Buy | 75.00 | 3.48 | 261.00 | 20,767.00 | |
| 2020-06-08 | Joseph C Galante | Director | Buy | 75.00 | 3.54 | 265.50 | 20,692.00 | |
| 2020-06-05 | Joseph C Galante | Director | Buy | 75.00 | 3.44 | 258.00 | 20,617.00 | |
| 2020-06-04 | Joseph C Galante | Director | Buy | 75.00 | 3.31 | 248.25 | 20,542.00 | |
| 2020-06-03 | Joseph C Galante | Director | Buy | 75.00 | 3.29 | 246.75 | 20,467.00 | |
| 2020-06-02 | Joseph C Galante | Director | Buy | 75.00 | 3.35 | 251.25 | 20,392.00 | |
| 2020-06-01 | Joseph C Galante | Director | Buy | 75.00 | 3.45 | 258.75 | 20,317.00 | |
| 2020-05-29 | Joseph C Galante | Director | Buy | 75.00 | 3.35 | 251.25 | 20,242.00 | |
| 2020-05-28 | Joseph C Galante | Director | Buy | 75.00 | 3.34 | 250.50 | 20,167.00 | |
| 2020-05-27 | Joseph C Galante | Director | Buy | 75.00 | 3.49 | 261.75 | 20,092.00 | |
| 2020-05-26 | Joseph C Galante | Director | Buy | 75.00 | 3.59 | 269.25 | 20,017.00 | |
| 2020-05-22 | Joseph C Galante | Director | Buy | 75.00 | 3.61 | 270.75 | 19,942.00 | |
| 2020-05-21 | Joseph C Galante | Director | Buy | 75.00 | 3.68 | 276.00 | 19,867.00 | |
| 2020-05-20 | Joseph C Galante | Director | Buy | 75.00 | 3.77 | 282.75 | 19,792.00 | |
| 2020-05-19 | Joseph C Galante | Director | Buy | 75.00 | 3.78 | 283.50 | 19,717.00 | |
| 2020-05-18 | Joseph C Galante | Director | Buy | 75.00 | 3.82 | 286.50 | 19,642.00 | |
| 2020-05-15 | Joseph C Galante | Director | Buy | 75.00 | 3.76 | 282.00 | 19,567.00 | |